Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pruralabine versus regorafenib in advanced hepatocellular carcinoma after failure of targeted therapy and immune checkpoint inhibitor treatment
CTR20254321Phase 3Active
- Sponsor
- Xi'an Xintong Pharmaceutical
- Start
- Nov 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of pralatrexate in hepatocellular carcinoma (HCC), sponsored by Xi'an Xintong Pharmaceutical. Started Nov 2025; status: active.
02
Drugs
pralatrexate
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20254321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254321.